Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep780 | Reproductive and Developmental Endocrinology | ECE2020

Radioidine (RAI) as a new therapy for the treatment of ovarian cancer through the sodium/iodide symporter (NIS)

Mirela Mielu Lidia , Paz Lopez-Molina Maria , Mingo-Casas Patricia , Rodal-Bravo Lucía , Diego-Hernandez Cristina , Pallarés Pilar , García-Jimenez Custodia , Martin-Duque Pilar , De la Vieja Antonio

Introduction: Ovarian cancer is the most lethal gynecological malignancy. Early diagnosis has a survival rate of 90%. Unfortunately, more than 70% of cases are diagnosed when the cancer has already metastasized, and survival rates do not exceed 30% in these cases. The sodium iodide symporter (NIS) is an integral plasma membrane glycoprotein expressed in the basolateral surface of the thyroid gland, where it mediates active transport of iodide. Radioiodide therapy (RAI) through...